Search Within

Kevin Joseph Curran

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (7)
Groups
  1. Pediatrics, Department of (23)
  2. Stem Cell Transplantation and Cellular Therapy Service (23)
  3. Survivorship Research (23)
  4. Center for Hematologic Malignancies (22)
  5. Department of Medicine (21)
  6. GSK Faculty (19)

More Groups

People
  1. Sergio Giralt (16)
  2. Richard O'Reilly (14)
  3. Andromachi Scaradavou (12)
  4. Miguel-Angel Perales (12)
  5. Nancy Kernan (12)
  6. Ann Jakubowski (11)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (2)
  5. 2020 (3)
  6. 2019 (1)

More Years

Publications
  1. Blood (6)
  2. Bone Marrow Transplantation (4)
  3. Blood Advances (3)
  4. Biology of Blood and Marrow Transplantation (2)
  5. Journal of Clinical Investigation (2)
  6. Cytotherapy (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. Nature Publishing Group (4)
  3. American Society for Clinical Investigation (2)
  4. Elsevier Inc. (2)
  5. American Society of Clinical Oncology (1)
  6. Elsevier Science Ltd. (1)

More Publishers

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
    Journal Article

    Prockop, S.; Doubrovina, E.; Suser, S.; Heller, G.; Barker, J.; Dahi, P.; Perales, M. A.; Papadopoulos, E.; Sauter, C.; Castro-Malaspina, H.; more...
    Journal of Clinical Investigation (2020)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; RivieĢ€re, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors
    Journal Article

    Praveen, A.; Friedman, D. N.; Sklar, C.; Oeffinger, K.; Castiel, M.; Kearney, J.; Singh, B.; Prockop, S. E.; Kernan, N. A.; Scaradavou, A.; more...
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • Germline mutations in cancer predisposition genes in a subset of pediatric oncology patients undergoing targeted solid tumor sequencing using matched normal DNA
    Meeting Abstract

    Walsh, M.; Shukla, N.; Joseph, V.; Kentsis, A.; Curran, K.; Kobos, R.; Arnold, A.; Harlan, M.; Kennedy, J.; Schrader, K.; more...
    Pediatric Blood and Cancer (2016)

    Fulltext@MSK | Save
  • T- cell depleted peripheral blood stem cell (TCD-PBSC) transplants secure consistent engraftment with low risk of acute or chronic GVHD and favorable disease free survival (DFS) and overall survival (OS) for pediatric patients (< 21 years) with AML in CR1
    Meeting Abstract

    Kernan, N. A.; Boulad, F.; Prockop, S. E.; Scaradavou, A.; Kobos, R.; Lehrman, R.; Klein, E.; Wolden, S.; Curran, K. J.; Hasan, A. N.; more...
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • T-cell depleted peripheral blood stem cell (TCD-PBSC) transplants secure consistent engraftment with low risk of acute or chronic Gvhd and favorable disease free survival (DFS) and overall survival (OS) for pediatric patients (<21 years) with AML in CR1 or CR2 or MDS including tMDS/AML
    Meeting Abstract

    Kernan, N. A.; Boulad, F.; Prockop, S.; Wolden, S.; Scaradavou, A.; Kobos, R.; Lehrman, R.; Klein, E.; Curran, K. J.; Hasan, A. N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y.; Wang, X. Y.; Purdon, T.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Two chemotherapy-based conditioning regimens compared to TBI-based conditioning secure consistent engraftment of T-cell depleted allogeneic HSCT, similarly low incidences of GVHD and favorable rates of disease-free survival (DFS)
    Meeting Abstract

    Koehne, G.; Boulad, F.; Barker, J.; Castro-Malaspina, H.; Curran, K.; Giralt, S.; Hasan, A.; Heller, G.; Hsu, K.; Jakubowski, A.; more...
    Bone Marrow Transplantation (2015)

    Fulltext@MSK | Save